FOCR offers path for validating ctDNA as an early endpoint for drug approval
Regulatory NewsMary Ellen Schneider
BiologicsBiotechnologyClinical TrialsDiagnosticsNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsMary Ellen SchneiderBiologicsBiotechnologyClinical TrialsDiagnosticsNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy